CN101151259B - 可用于抑制chk1的杂芳基脲衍生物 - Google Patents
可用于抑制chk1的杂芳基脲衍生物 Download PDFInfo
- Publication number
- CN101151259B CN101151259B CN2006800101504A CN200680010150A CN101151259B CN 101151259 B CN101151259 B CN 101151259B CN 2006800101504 A CN2006800101504 A CN 2006800101504A CN 200680010150 A CN200680010150 A CN 200680010150A CN 101151259 B CN101151259 B CN 101151259B
- Authority
- CN
- China
- Prior art keywords
- compound
- chk1
- methyl
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- TYBZMBVGJAZQQP-UHFFFAOYSA-N Cc(c(C)c1)cc(NC(Nc2ncc(C)nc2)=O)c1OCC1OCCCNC1 Chemical compound Cc(c(C)c1)cc(NC(Nc2ncc(C)nc2)=O)c1OCC1OCCCNC1 TYBZMBVGJAZQQP-UHFFFAOYSA-N 0.000 description 1
- ZVHPDSOOZVPXMU-UHFFFAOYSA-N Cc(c(C)c1)cc(NC(Nc2ncc(C)nc2)=O)c1OCC1OCCNC1 Chemical compound Cc(c(C)c1)cc(NC(Nc2ncc(C)nc2)=O)c1OCC1OCCNC1 ZVHPDSOOZVPXMU-UHFFFAOYSA-N 0.000 description 1
- YGASGTANKVESKW-UHFFFAOYSA-N Cc(c(Cl)c1)cc(OCC2OCCNC2)c1NC(Nc1ncc(C)nc1)=O Chemical compound Cc(c(Cl)c1)cc(OCC2OCCNC2)c1NC(Nc1ncc(C)nc1)=O YGASGTANKVESKW-UHFFFAOYSA-N 0.000 description 1
- YGASGTANKVESKW-CYBMUJFWSA-N Cc(c(Cl)c1)cc(OC[C@@H]2OCCNC2)c1NC(Nc1ncc(C)nc1)=O Chemical compound Cc(c(Cl)c1)cc(OC[C@@H]2OCCNC2)c1NC(Nc1ncc(C)nc1)=O YGASGTANKVESKW-CYBMUJFWSA-N 0.000 description 1
- ZNLXMIFDDUGZFX-UHFFFAOYSA-N Cc(cc1)cc(NC(Nc2ncc(C#N)nc2)=O)c1OCC1OCCN(C)C1 Chemical compound Cc(cc1)cc(NC(Nc2ncc(C#N)nc2)=O)c1OCC1OCCN(C)C1 ZNLXMIFDDUGZFX-UHFFFAOYSA-N 0.000 description 1
- ZNLXMIFDDUGZFX-OAHLLOKOSA-N Cc(cc1)cc(NC(Nc2ncc(C#N)nc2)=O)c1OC[C@@H]1OCCN(C)C1 Chemical compound Cc(cc1)cc(NC(Nc2ncc(C#N)nc2)=O)c1OC[C@@H]1OCCN(C)C1 ZNLXMIFDDUGZFX-OAHLLOKOSA-N 0.000 description 1
- SDSVUOMQRYQEMB-INIZCTEOSA-N Cc(nc1)cnc1NC(Nc(cc(CCC1)c1c1)c1OC[C@H]1OCCNC1)=O Chemical compound Cc(nc1)cnc1NC(Nc(cc(CCC1)c1c1)c1OC[C@H]1OCCNC1)=O SDSVUOMQRYQEMB-INIZCTEOSA-N 0.000 description 1
- CGLAJMVPWFEJDG-ZDUSSCGKSA-N Cc(nc1)cnc1NC(Nc(cc(cc1)Br)c1OC[C@H]1OCCNC1)=O Chemical compound Cc(nc1)cnc1NC(Nc(cc(cc1)Br)c1OC[C@H]1OCCNC1)=O CGLAJMVPWFEJDG-ZDUSSCGKSA-N 0.000 description 1
- LTMBULZIIXFVGE-UHFFFAOYSA-N Cc(nc1)cnc1NC(Nc(cc(cc1)Cl)c1OCC1OCCCNC1)=O Chemical compound Cc(nc1)cnc1NC(Nc(cc(cc1)Cl)c1OCC1OCCCNC1)=O LTMBULZIIXFVGE-UHFFFAOYSA-N 0.000 description 1
- ZAZWOSRSPCSJLQ-AWEZNQCLSA-N Cc(nc1)cnc1NC(Nc(cc(cc1)Cl)c1OC[C@H]1OCCN(CN)C1)=O Chemical compound Cc(nc1)cnc1NC(Nc(cc(cc1)Cl)c1OC[C@H]1OCCN(CN)C1)=O ZAZWOSRSPCSJLQ-AWEZNQCLSA-N 0.000 description 1
- OVNYZXXPIXDCKM-NSHDSACASA-N O=C(Nc1cc(Cl)ccc1OC[C@H]1OCCNC1)Nc1ncc(C(F)(F)F)nc1 Chemical compound O=C(Nc1cc(Cl)ccc1OC[C@H]1OCCNC1)Nc1ncc(C(F)(F)F)nc1 OVNYZXXPIXDCKM-NSHDSACASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66602605P | 2005-03-29 | 2005-03-29 | |
| US60/666,026 | 2005-03-29 | ||
| PCT/US2006/011584 WO2006105262A1 (en) | 2005-03-29 | 2006-03-29 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101022112A Division CN102219784A (zh) | 2005-03-29 | 2006-03-29 | 可用于抑制chk1的杂芳基脲衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101151259A CN101151259A (zh) | 2008-03-26 |
| CN101151259B true CN101151259B (zh) | 2011-06-15 |
Family
ID=36677174
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800101504A Expired - Fee Related CN101151259B (zh) | 2005-03-29 | 2006-03-29 | 可用于抑制chk1的杂芳基脲衍生物 |
| CN2011101022112A Pending CN102219784A (zh) | 2005-03-29 | 2006-03-29 | 可用于抑制chk1的杂芳基脲衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101022112A Pending CN102219784A (zh) | 2005-03-29 | 2006-03-29 | 可用于抑制chk1的杂芳基脲衍生物 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8093244B2 (https=) |
| EP (2) | EP1869020B1 (https=) |
| JP (2) | JP5117374B2 (https=) |
| KR (2) | KR100912998B1 (https=) |
| CN (2) | CN101151259B (https=) |
| AR (1) | AR056645A1 (https=) |
| AT (1) | ATE490248T1 (https=) |
| AU (1) | AU2006230337B2 (https=) |
| BR (1) | BRPI0609667A2 (https=) |
| CA (1) | CA2602199C (https=) |
| CR (1) | CR9395A (https=) |
| CY (1) | CY1111240T1 (https=) |
| DE (1) | DE602006018590D1 (https=) |
| DK (1) | DK1869020T3 (https=) |
| EA (1) | EA011287B1 (https=) |
| ES (1) | ES2356068T3 (https=) |
| HR (1) | HRP20100678T1 (https=) |
| IL (1) | IL185481A0 (https=) |
| MA (1) | MA29439B1 (https=) |
| MX (1) | MX2007012116A (https=) |
| NO (1) | NO20074944L (https=) |
| NZ (1) | NZ561458A (https=) |
| PL (1) | PL1869020T3 (https=) |
| PT (1) | PT1869020E (https=) |
| RS (1) | RS51616B (https=) |
| SI (1) | SI1869020T1 (https=) |
| TN (1) | TNSN07369A1 (https=) |
| TW (1) | TWI375559B (https=) |
| UA (1) | UA92164C2 (https=) |
| WO (1) | WO2006105262A1 (https=) |
| ZA (1) | ZA200707715B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5221367A (en) | 1988-08-03 | 1993-06-22 | International Business Machines, Corp. | Strained defect-free epitaxial mismatched heterostructures and method of fabrication |
| MY150649A (en) * | 2006-10-20 | 2014-02-14 | Icos Corp | Compositions of chk1 inhibitors |
| CN101200429B (zh) * | 2006-12-13 | 2012-08-22 | 上海睿智化学研究有限公司 | 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法 |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| HRP20220351T1 (hr) | 2016-02-04 | 2022-05-13 | Pharmaengine, Inc. | 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| US20200108074A1 (en) * | 2017-03-31 | 2020-04-09 | Seattle Genetics, Inc. | Combinations of chk1- and wee1- inhibitors |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| US12404332B2 (en) * | 2020-03-13 | 2025-09-02 | Research Development Foundation | Methods for diagnosing and treating cancers |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014765A1 (en) * | 2002-05-29 | 2004-01-22 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| US20040259885A1 (en) * | 2002-08-13 | 2004-12-23 | Gaoquan Li | Urea kinase inhibitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293552A (en) | 1978-02-27 | 1981-10-06 | Eli Lilly And Company | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas |
| US6174993B1 (en) | 1997-05-21 | 2001-01-16 | The Children's Medical Center Corp. | Short peptides which selectively modulate the activity of serine/threonine kinases |
| US6218109B1 (en) | 1997-09-05 | 2001-04-17 | Baylor College Of Medicine | Mammalian checkpoint genes and proteins |
| GB9718952D0 (en) | 1997-09-05 | 1997-11-12 | Medical Res Council | Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods |
| JP2001518501A (ja) | 1997-10-06 | 2001-10-16 | ビーエーエスエフ アクチェンゲゼルシャフト | インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体 |
| EP1135135A4 (en) | 1998-09-18 | 2006-08-09 | Smithkline Beecham Corp | CHK1 KINASE INHIBITORS |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| WO2001057206A2 (en) | 2000-02-03 | 2001-08-09 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
| AU2001243226A1 (en) | 2000-02-25 | 2001-09-03 | The Regents Of The University Of California | Scytonemin and methods of using thereof |
| US6211164B1 (en) | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
| US6534691B2 (en) | 2000-07-18 | 2003-03-18 | E. I. Du Pont De Nemours And Company | Manufacturing process for α-olefins |
| ATE295354T1 (de) | 2000-08-18 | 2005-05-15 | Agouron Pharma | Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen |
| CA2434066A1 (en) | 2001-01-26 | 2002-09-12 | Pharmacia Italia S.P.A. | Chromane derivatives, process for their preparation and their use as antitumor agents |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| US7064215B2 (en) | 2001-07-03 | 2006-06-20 | Chiron Corporation | Indazole benzimidazole compounds |
| WO2003029241A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| WO2003028731A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| DE60229975D1 (de) | 2001-10-04 | 2009-01-02 | Smithkline Beecham Corp | Nf-kb-inhibitoren |
| AU2002356871A1 (en) | 2001-10-30 | 2003-05-12 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| US20030119839A1 (en) | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| EP1501831A1 (en) | 2002-04-26 | 2005-02-02 | Warner-Lambert Company Llc | Inhibitors of checkpoint kinases (wee1 and chk1) |
| US20040034038A1 (en) | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| BR0316680A (pt) | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
| CA2512683C (en) | 2003-01-09 | 2010-03-16 | Pfizer Inc. | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy |
| EP1765808A1 (en) * | 2004-06-25 | 2007-03-28 | ICOS Corporation | Bisarylurea derivatives useful for inhibiting chk1 |
| CA2679908A1 (en) | 2009-09-23 | 2011-03-23 | Shell Internationale Research Maatschappij B.V. | Closed loop solvent extraction process for oil sands |
| CN104407475B (zh) | 2014-12-04 | 2017-04-05 | 厦门天马微电子有限公司 | 液晶显示面板 |
-
2006
- 2006-03-29 HR HR20100678T patent/HRP20100678T1/hr unknown
- 2006-03-29 EA EA200702094A patent/EA011287B1/ru not_active IP Right Cessation
- 2006-03-29 PL PL06748900T patent/PL1869020T3/pl unknown
- 2006-03-29 EP EP06748900A patent/EP1869020B1/en not_active Expired - Lifetime
- 2006-03-29 AU AU2006230337A patent/AU2006230337B2/en not_active Ceased
- 2006-03-29 PT PT06748900T patent/PT1869020E/pt unknown
- 2006-03-29 AR ARP060101226A patent/AR056645A1/es unknown
- 2006-03-29 RS RS20110053A patent/RS51616B/sr unknown
- 2006-03-29 SI SI200630870T patent/SI1869020T1/sl unknown
- 2006-03-29 ES ES06748900T patent/ES2356068T3/es not_active Expired - Lifetime
- 2006-03-29 DE DE602006018590T patent/DE602006018590D1/de not_active Expired - Lifetime
- 2006-03-29 JP JP2008504337A patent/JP5117374B2/ja not_active Expired - Fee Related
- 2006-03-29 CN CN2006800101504A patent/CN101151259B/zh not_active Expired - Fee Related
- 2006-03-29 CA CA2602199A patent/CA2602199C/en not_active Expired - Fee Related
- 2006-03-29 UA UAA200710711A patent/UA92164C2/ru unknown
- 2006-03-29 EP EP10189889A patent/EP2330105A1/en not_active Withdrawn
- 2006-03-29 NZ NZ561458A patent/NZ561458A/en not_active IP Right Cessation
- 2006-03-29 MX MX2007012116A patent/MX2007012116A/es active IP Right Grant
- 2006-03-29 AT AT06748900T patent/ATE490248T1/de active
- 2006-03-29 KR KR1020077022281A patent/KR100912998B1/ko not_active Expired - Fee Related
- 2006-03-29 WO PCT/US2006/011584 patent/WO2006105262A1/en not_active Ceased
- 2006-03-29 US US11/908,416 patent/US8093244B2/en not_active Expired - Fee Related
- 2006-03-29 CN CN2011101022112A patent/CN102219784A/zh active Pending
- 2006-03-29 TW TW095110859A patent/TWI375559B/zh not_active IP Right Cessation
- 2006-03-29 DK DK06748900.5T patent/DK1869020T3/da active
- 2006-03-29 BR BRPI0609667-0A patent/BRPI0609667A2/pt not_active IP Right Cessation
- 2006-03-29 KR KR1020097002925A patent/KR20090031459A/ko not_active Ceased
-
2007
- 2007-08-23 IL IL185481A patent/IL185481A0/en unknown
- 2007-09-07 ZA ZA200707715A patent/ZA200707715B/xx unknown
- 2007-09-26 CR CR9395A patent/CR9395A/es unknown
- 2007-09-28 TN TNP2007000369A patent/TNSN07369A1/en unknown
- 2007-10-01 NO NO20074944A patent/NO20074944L/no not_active Application Discontinuation
- 2007-10-26 MA MA30325A patent/MA29439B1/fr unknown
-
2009
- 2009-05-20 JP JP2009122107A patent/JP2009227682A/ja active Pending
-
2011
- 2011-02-03 CY CY20111100117T patent/CY1111240T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014765A1 (en) * | 2002-05-29 | 2004-01-22 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| US20040259885A1 (en) * | 2002-08-13 | 2004-12-23 | Gaoquan Li | Urea kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100861829B1 (ko) | 방사선 증감제 및 화학적 감작제로서 유용한 아릴, 및헤테로아릴 우레아 ｃｈｋ１ 억제제 | |
| US7560462B2 (en) | Compounds useful for inhibiting CHK1 | |
| JP2009227682A (ja) | Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体 | |
| US20220402900A1 (en) | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer | |
| JP2008535830A5 (https=) | ||
| US20080318974A1 (en) | Compounds Useful for Inhibiting Chk1 | |
| KR101457027B1 (ko) | 트리아진 유도체와 이들의 치료적 용도 | |
| CN101006075A (zh) | 可用于抑制chk1的双芳基脲衍生物 | |
| HK1119670B (en) | Heteroaryl urea derivatives useful for inhibiting chk1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110615 Termination date: 20160329 |